Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP253817.RALNsOfj94dyjQFzn_d0X37ArUOrccvHndb4UjkUmMsBg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP253817.RALNsOfj94dyjQFzn_d0X37ArUOrccvHndb4UjkUmMsBg130_assertion type Assertion NP253817.RALNsOfj94dyjQFzn_d0X37ArUOrccvHndb4UjkUmMsBg130_head.
- NP253817.RALNsOfj94dyjQFzn_d0X37ArUOrccvHndb4UjkUmMsBg130_assertion description "[Since the Bayer preparation is no longer available for treatment of large series of patients with ALL, the present study was designed to prospectively evaluate coagulation and fibrinolytic changes in leukaemic children receiving different doses of Medac ASP, which is now available for treatment of childhood ALL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP253817.RALNsOfj94dyjQFzn_d0X37ArUOrccvHndb4UjkUmMsBg130_provenance.
- NP253817.RALNsOfj94dyjQFzn_d0X37ArUOrccvHndb4UjkUmMsBg130_assertion evidence source_evidence_literature NP253817.RALNsOfj94dyjQFzn_d0X37ArUOrccvHndb4UjkUmMsBg130_provenance.
- NP253817.RALNsOfj94dyjQFzn_d0X37ArUOrccvHndb4UjkUmMsBg130_assertion SIO_000772 8857948 NP253817.RALNsOfj94dyjQFzn_d0X37ArUOrccvHndb4UjkUmMsBg130_provenance.
- NP253817.RALNsOfj94dyjQFzn_d0X37ArUOrccvHndb4UjkUmMsBg130_assertion wasDerivedFrom befree-20150227 NP253817.RALNsOfj94dyjQFzn_d0X37ArUOrccvHndb4UjkUmMsBg130_provenance.
- NP253817.RALNsOfj94dyjQFzn_d0X37ArUOrccvHndb4UjkUmMsBg130_assertion wasGeneratedBy ECO_0000203 NP253817.RALNsOfj94dyjQFzn_d0X37ArUOrccvHndb4UjkUmMsBg130_provenance.